Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?
暂无分享,去创建一个
Laurence Collette | Jean-Pascal Machiels | François Jamar | L. Collette | E. Coche | J. Machiels | B. Tombal | F. Lecouvet | F. Jamar | P. Omoumi | E. Danse | B. Vande Berg | Bertrand Tombal | Frédéric E Lecouvet | Jawad El Mouedden | Emmanuel Coche | Etienne Danse | Bruno Vande Berg | Patrick Omoumi | J. El Mouedden | B. vande Berg
[1] H. Schirrmeister,et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] R. Low,et al. Abdominal MRI advances in the detection of liver tumours and characterisation. , 2007, The Lancet. Oncology.
[3] F. Mottaghy,et al. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. , 2011, European urology.
[4] C. Abbou,et al. EAU guidelines on prostate cancer. , 2009, European urology.
[5] P. Therasse,et al. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] H. Jadvar. Prostate Cancer: PET with 18F-FDG, 18F- or 11C-Acetate, and 18F- or 11C-Choline , 2011, The Journal of Nuclear Medicine.
[7] I. Narabayashi,et al. 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience , 2007, Annals of nuclear medicine.
[8] B. Tombal,et al. Whole-body MRI (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and measure bone metastases in prostate cancer (PCa) , 2010, European Radiology.
[9] G. Beaudoin,et al. Towards dose reduction in CT: patient radiation dose assessment for CT examinations at university health center in Canada and comparison with national diagnostic reference levels. , 2012, Radiation protection dosimetry.
[10] F. Saad,et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] J. Mohler. The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.
[12] N. Blumstein,et al. Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventional MR and 11C-choline PET/CT for detection of bone metastases. , 2008, Radiology.
[13] U. Capitanio,et al. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. , 2010, European urology.
[14] P. Therasse,et al. Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases , 2005, The Prostate.
[15] G. Cook,et al. MRI or bone scan or both for staging of prostate cancer? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Susan Halabi,et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] R. Eeles,et al. Whole‐body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer , 2009, Journal of medical imaging and radiation oncology.
[18] J. Choi,et al. Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. , 2008, Radiology.
[19] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[20] Alan W Partin,et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. , 2005, JAMA.
[21] J Kotzerke,et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[22] M. Okada,et al. [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.
[23] B. Carey,et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. , 2011, European urology.
[24] O. Schober,et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. , 2001, AJR. American journal of roentgenology.
[25] J. Hugosson,et al. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial. , 2007, European urology.
[26] Anthony D'Amico,et al. Prostate cancer. Clinical practice guidelines in oncology. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.
[27] H. Thoeny,et al. Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: a critical analysis of the literature. , 2012, European urology.
[28] Hironobu Nakamura,et al. Whole body MRI for detecting metastatic bone tumor: comparison with bone scintigrams. , 2005, Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine.
[29] T. Takahara,et al. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. , 2004, Radiation medicine.
[30] Dow-Mu Koh,et al. Practical aspects of assessing tumors using clinical diffusion-weighted imaging in the body. , 2007, Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine.
[31] U. Metser,et al. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[32] Anke M Hövels,et al. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. , 2008, The Lancet. Oncology.
[33] E. Adang,et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. , 2008, Clinical radiology.